Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in the EU / 2026-526361-15-00
Authorised, not yet recruiting Phase II

An Open-Label Extension, One-Year, Safety, and Efficacy Study of SPN-817 in Adults With Focal Onset Seizures

2026-526361-15-00 · tracked via the Priya Life Science EU tracker
Sponsor
Supernus Pharmaceuticals Inc
Sponsor type
Pharmaceutical company
Therapeutic area
Nervous System Diseases
Decision date
20/10/2026
Enrollment target
45
Sites
Poland, Bulgaria, Hungary

Condition studied

Focal Onset Seizures

Investigational medicinal product(s)

Huperzine APlacebo capsules matching SPN-817 capsules for all strengths to be used during the Dose Titration/Bridging Period.

Every trial of Huperzine A across our registers →

Eligibility

Age group
18-64 years, 65+ years
Sex
Female, Male

Primary endpoint

1. Incidence of treatment-emergent adverse events (TEAEs), 2. Change from baseline (CFB) in clinical laboratory test results at scheduled visits, 3. CFB in vital signs measurements at scheduled visits, 4. CFB in 12-lead electrocardiogram (ECG) findings at scheduled visits, 5. Columbia-Suicide Severity Rating Scale (C-SSRS) scores at scheduled visits

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2026-526361-15-00 on CTIS ↗ ← All trials in the EU